Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Endocrine 3Genitourinary 1

Conditions

Carcinoma, Renal Cell 84Kidney Neoplasms 22Prostatic Neoplasms 14Neoplasm Metastasis 10Neoplasms 9Urinary Bladder Neoplasms 8Carcinoma, Hepatocellular 5Liver Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Pancreatic Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma 3Urethral Neoplasms 2Sarcoma 2Multiple Myeloma 2Hematologic Neoplasms 2Glioblastoma 2Financial Stress 2Wilms Tumor 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Testicular Neoplasms 1Stomach Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Germ Cell and Embryonal 1

Interventions

entrectinib 2Trastuzumab 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tovorafenib 1tipifarnib 1sargramostim 1alectinib 1aldesleukin 1Sorafenib 1Rosiglitazone 1Ritonavir 1Radiotherapy 1Paclitaxel 1Interviews as Topic 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Docetaxel 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × Sorafenib × Genitourinary × Clear all
NCT01502410 2018-06-26

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 14 charts
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Wilms Tumor, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡